Objective: To ascertain the risk of a new vascular event (NVE) occurring after ischemic stroke and evaluate differences in risk based on stroke subtype.
follows previously described patient care methods and secondary prevention measures according to the most recent European and American guidelines. 12 We designed a complementary, prospective, observational registry of patients admitted from June 2007 to May 2010 (n 5 1,002) who presented with NVE in the study follow-up period after having an ischemic stroke or TIA. Maximal follow-up was 60 months (through June 2012). We included all patients, regardless of history of cerebrovascular, coronary, or peripheral artery disease (PAD). For the defined follow-up period, detection of a 2% difference between stroke subtypes required a sample size of 93 cases for each stroke subtype. Exclusion criteria included the following: fatal stroke 11 within 28 days of stroke onset (n 5 163; 16.3%); residence outside the hospital service area, as it deterred long-term follow-up (n 5 51; 6.1%); and stroke categorized according to Stop Stroke Study Trial of Org 10172 in Acute Stroke Treatment (SSS-TOAST) (an evidence-based causative classification system for ischemic stroke) 7 as "other causes" (n 5 32; 4.1%). We also excluded patients who did not undergo any extracranial or intracranial arterial studies to establish etiology (n 5 4; 0.5%), those who did not present at the 3-month follow-up appointment (n 5 3; 0.4%), and those who did not provide informed consent to participate in this study (n 5 1; 0.1%) (figure e-1 on the Neurology ® Web site at www. neurology.org).
Follow-up consisted of a clinic visit at 3 months and then, at the physician's discretion, a clinic appointment or telephone contact every 6 months thereafter. In the case of patients lost to followup after the 3-month visit (n 5 62; 8.3%), we consulted electronic medical records, the primary care physician, or hospital admissions records. At study conclusion, we reviewed all patient events and death records. For all cases of NVE, we accessed the clinical record to determine all tests and procedures performed and events certified by a neurologist, cardiologist, or vascular surgeon. A member of the investigative team validated each event, and when necessary we contacted the attending doctors for confirmation.
Endpoint. The study endpoint was presentation with an NVE, defined according to the REACH study criteria 11 : vascular death, nonfatal stroke, nonfatal myocardial infarction (MI), or hospitalization for an atherothrombotic event, including vascular interventions. We did not include patients in our analysis who presented with NVEs that occurred within 28 days of stroke onset. We did not consider vascular interventions performed at least 28 days after the stroke as a secondary prevention strategy or as a hospitalization event unless associated with a further vascular complication. We discovered 2 vascular deaths following utilization of secondary prevention strategies among the patients studied. One patient died from cerebral hemorrhage after intracranial stent placement and one from cardiac complications after carotid artery surgery. Study variables. We recorded age, sex, and anthropometric measurements, identified vascular risk factors according to REACH definitions, and included hypertension, dyslipidemia, diabetes, atrial fibrillation, heart failure, and obesity. 11 In addition, we determined involvement of the following vascular disorders using REACH criteria: 1) documented coronary artery disease (CAD), consisting of one or more of the following: stable or unstable angina, history of percutaneous coronary intervention or surgery, or previous MI; 2) documented PAD, consisting of current intermittent claudication with an ankle brachial index of less than 0.9 or a history of intermittent claudication, together with a previous related intervention, such as amputation; or 3) documented cerebrovascular disease, consisting of a hospital or neurologist diagnosis of TIA or ischemic stroke.
Following the REACH methodology and based on previous data, [13] [14] [15] we divided the cohort into 4 subgroups according to atherosclerotic burden (AB), using the following scores: 0 points, fewer than 3 vascular risk factors and not affecting other vascular territories (CAD or PAD); 1 point, 3 or more risk factors; 2 points, 1 vascular territory affected (in addition to cerebrovascular); and 3 points, 2 vascular territories affected. AB scores of 2 and 3 were independent of the number of vascular risk factors. For each patient, we determined stroke subtype according to SSS-TOAST classification 7 : largeartery atherosclerosis (LAA), small-artery disease (SAD), cardioaortic embolism (CE), undetermined causes, and unclassified strokes (more than one apparent mechanism). Physicians assessed patients with LAA for the presence of intracranial disease.
Standard protocol approvals, registrations, and patient consents. The local ethics committee approved the study proposal. We obtained written informed consent from all participants (or a designated representative).
Statistical analysis. For continuous variables, we present data as means 6 SD and categorical variables as frequencies and percentages. We used t test and analysis of variance to evaluate the differences in means for continuous variables and the Fisher exact test for categorical variables. We calculated the relative average rate (events per patient-year) as the number of new events found during followup divided by the number of years at-risk patients were followed up. Further, we categorized vascular risk factors and history of vascular events into 4 subgroups based on defined AB scores. We used Cox regression survival analysis to estimate multivariate hazard ratio (HR) with 95% confidence interval (CI) for an NVE. Reference subgroups in multivariate analysis were those with an AB score of 0 and the stroke subtype with the lowest percentage of events (undetermined stroke). We adjusted all multivariate models by age and sex and considered 2-sided p values ,0.05 as significant. A team biostatistician reviewed all statistical analyses.
RESULTS
The final study sample consisted of 748 patients. Demographics and vascular risk factors are shown in table 1. All patients completed the follow-up through June 2012 except 124 cases that were lost to follow-up (n 5 14, 11 discharged home outside the study area and 3 lost for unknown reasons) or death due to nonvascular Table 3 shows the distribution of AB by stroke subtype and its relationship to NVE rate, which correlated to NVEs for the SAD, unclassified, and LAA subtypes. When adjusted for age, sex, AB score, and stroke subtype, multivariate analysis showed associations between risk for NVE after stroke with AB and the same 3 stroke subtypes (table 4, figure 1 , figure e-2). Using . DISCUSSION We demonstrate groundbreaking evidence that ischemic stroke is a high-risk vascular disease (.20% overall risk of vascular complications at 10 years) 16 ; further, we found independent differences in patients' vascular risk dependent upon stroke subtype classification by SSS-TOAST, a modern scale that focuses on the etiologic cause of the stroke. Our observations regarding NVE risk after stroke are within the range described by previous studies that included long-term follow-up (17.4% to 41.3% at 4 or 5 years) and different vascular endpoints (MI, vascular death, or vascular events). 3, 5, 17, 18 Vascular risk after ischemic stroke is less well-described and available data are also heterogeneous because of differences in the length of follow-up and the definitions used. Most data come from the REACH register, a multicountry, multicenter study designed to mimic the best available epidemiologic data on atherothrombosis or at-risk outpatients in each participating country, which included 18,189 patients with history of cerebrovascular disease. 10 REACH reported a 21.05% NVE rate at 2-year follow-up. 15 Our patient profile differs from but complements the REACH dataset in that we report very similar data over a longer average follow-up, collected only for hospitalized patients in a single center.
Although some studies report no differences in risk based on stroke subtype, [19] [20] [21] new American Heart Association recommendations include only patients with atherothrombotic stroke in the group at high coronary risk, which suggests a need for further analysis of other stroke subtypes. 1 We specifically designed the present study to detect any NVE after stroke, and our results confirm the high-risk status of patients with LAA strokes, 1, 22 as well as those with unclassified and CE strokes. Traditionally, patients with unclassified stroke subtype (more than one causal mechanism of stroke) have been classified together with those whose cause of stroke is unknown (undetermined, according to the TOAST classification). As a result, the actual importance of the unclassified subtype in the overall context of stroke and the associated risk of vascular disease or of recurrence was not known. In our cohort, unclassified subtype made up 5% of all strokes and, as might be surmised from their multiple causes, patients in this category had the highest vascular risk, along with patients with LAA subtype. Given the important differences in risk between the unclassified and undetermined cause subtypes, this result warrants further study.
Our results also indicate greater vascular risk in patients with CE stroke subtype. In these patients, increased vascular risk can be explained by a high risk of embolism, primarily cerebrovascular but also in the peripheral arteries. Nonetheless, the RE-LY study 23 reports that a control group of isolated atrial fibrillation patients taking warfarin had more ischemic cardiac events and cardiac deaths than cerebrovascular events. Therefore, we must take into account the major risk of noncerebrovascular complications in these patients.
SAD is an especially controversial stroke subtype. Contradictory prognostic data have been published; studies show greater vascular risk on the one hand, along with worse prognosis in the very long term, 21, 24, 25 and on the other hand lower risk of recurrence and disability. 19, 22, 26 Although stroke patients with SAD have the same vascular risk factors as other subtypes, the distinct absence of physiopathology associated with LAA or structural heart disease lowers their vascular risk according to our results. Occurrence and distribution of vascular complications are almost identical to those recently published in a lengthy international cohort study of rigorously selected patients with SAD (SPS3 study) and a follow-up period similar to ours. 27 Patients in the undetermined stroke subtype in whom an exhaustive cardioembolism study is negative have traditionally been described as having low vascular risk and low stroke recurrence. 28 A more recent study reports a higher recurrence risk in patients with undetermined cause of stroke than in those with SAD. 29 In our study, however, the recurrence rate was low and similar in both subtypes.
In addition to our primary objective, we assessed other aspects that might be related to increased vascular risk. As might be expected, the percentage of individuals at risk of an NVE was higher in the presence of dyslipidemia, heart failure, and history of CAD, PAD, or stroke. Curiously, dyslipidemia is included in CAD and PAD scales but not in scales validated to assess risk after stroke. 3 Only the SPI-II and REACH register evaluated heart failure, which may be an important vascular risk factor. 3, 11 Even though we did not aim to establish these factors as predictive of vascular risk after stroke, our results strongly support their inclusion in future risk estimation.
In our study, similar to other reports, 13, 14, 30 we found that the number of vascular territories previously affected (AB) independently correlated with the NVE occurrence. Moreover, we found a clear increase in NVE risk based on the AB score in SAD and LAA subtype patients. Therefore, AB analysis may be a good tool for assessment of vascular risk in patients with a hypothetical low-risk profile.
Finally, it is well-known that in patients with ischemic stroke, NVEs are usually cerebrovascular. 15, 22, 31 We found this as well in that more than half of NVEs were cerebrovascular. Fatal and nonfatal MIs and nonneurologic cause of death were less common. As a result, we only identified differences between stroke subtypes in terms of risk for NVE. To further explore this question, we reanalyzed our data, excluding any patient who presented with a new cerebrovascular event, and obtained results very similar to those discussed above with the same independent differences for stroke subtypes. Noncerebrovascular risk was highest in the unclassified subtype, followed by the LAA subtype. We did not have sufficient numbers to determine coronary risk in each stroke subtype.
Despite secondary prevention measures, we know that a high number of patients will present with an NVE over the course of prolonged follow-up after stroke. Observed differences in vascular risk based on stroke subtype are logical, taking into account the different causal mechanisms involved. Future studies aimed at evaluating the vascular risk of stroke patients must take stroke subtype into account. Vascular risk is lower in patients with SAD or undetermined stroke and higher when more than one causal mechanism or an atherothrombotic mechanism is determined. Therefore, it is essential to analyze cases of undetermined stroke as a subtype distinct from unclassified strokes. In stroke patients with SAD, the lower risk score for an NVE may be adjusted in accordance with the AB score.
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